Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 10/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17802520 | 0.86 | ESR2 (0.40) | ESR2LPLLIPGIDO1TDO2 | |
| SCHEMBL907049 | 0.79 | KDM4E (0.40) | LPLLIPGIDO1TDO2SNCA | |
| SCHEMBL5074870 | 0.77 | MEN1 (0.51) | ESR2LPLLIPGIDO1TDO2 | |
| SCHEMBL31387338 | 0.76 | IRAK4 (0.39) | LPLLIPGIDO1TDO2SNCA | |
| SCHEMBL17113535 | 0.76 | IRAK4 (0.39) | ESR2LPLLIPGIDO1TDO2 | |
| SCHEMBL17113584 | 0.76 | LPL (0.41) | ESR2LPLLIPGIDO1TDO2 | |
| SCHEMBL31752127 | 0.75 | IDO1 (0.39) | ESR2LPLLIPGIDO1TDO2 | |
| SCHEMBL30928610 | 0.75 | IDO1 (0.39) | ESR2LPLLIPGIDO1TDO2 | |
| SCHEMBL26442788 | 0.74 | ESR2 (0.47) | ESR2NAMPT | |
| SCHEMBL31394882 | 0.74 | LPL (0.43) | ESR2LPLLIPGIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032454-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032454-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | ESR2 735/4885LPL 4477/4885LIPG 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.